BSECompany Update3 Nov 2026 · 3 Nov 2026, 07:44 pm
Submission of Investor Presentation for the Earnings Call scheduled on Wednesday, November 04, 2026.
Evonile Pharma Ltd · 500672
✦ AI SummaryResults
Evonile Pharma Ltd submitted an investor presentation for an earnings call scheduled on November 04, 2026, under Regulation 30 of the SEBI Listing Regulations.
Analysis Scores
Earnings Impact5/10
Growth Catalyst6/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Evonile Pharma Ltd - 500672 - Announcement under Regulation 30 (LODR)-Investor Presentation
Attachments (1)
📄pdf
Download →
3b6c14a5-4a02-43ff-ad7a-a6af35399083.pdf
View document text
Evonile Pharma Limited
(formerly known as Novartis India Limited)
November 03, 2026
The Secretary,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001
Scrip Code: 500672
Subject: Submission of Presentation for the Earnings Call scheduled with Investors / Analyst s to be held on
Wednesday, November 04, 2026 .
Dear Sir/Madam,
This is further to our intimation dated October 26, 2026, submitted pursuant to Regulation 30 read with Part A
of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements)
Regulations, 2015, as amended (th e “SEBI Listing Regulations”), regarding the Earnings Call with investors and
analysts o f Evonile Pharma Limited (formerly known as Novartis India Limited) (the “Company”), scheduled
to be held on Wednesday, November 04, 2026 at 2:30 P.M. (IST) through virtual mode .
In compliance with Regulation 30 read with Part A of Schedule III of the SEBI Listing Regulations, we hereby
enclose the investor presentation to be made at the aforesaid Earnings Call and request you to take the same
on record and disseminate it on your w ebsite.
Pursuant to Regulation 46(2) of the SEBI Listing Regulations, the aforesaid presentation is also available on the
Company's website and can be accessed at: https://evonilepharma.com/earnings -call/
We hereby confirm that the enclosed presentation does not contain any unpublished price sensitive information
and that nothing contained therein shall be construed as unpublished price sensitive information within the
meaning of the applicable provisions o f the SEBI Listing Regulations and other applicable laws.
This disclosure is being made for your information and records.
Kindly take the above on record.
Thank you.
For Evonile Pharma Limited
(formerly known as Novartis India Limited )
Chandni Maru
Company Secretary and Compliance Officer
A60291
Registered Office: Inspire BKC, 7th Floor, Bandra -Kurla Complex, Bandra (East) , Mumbai - 400051, Maharashtra, India .
CIN: L24200MH1947PLC006104 | T el: +91 22 50243000
Email: investor.relations@evonilepharma.com | W ebsite: www.evonilepharma.com
(formerly known as Novartis India Limited)
I N V E S T O R P R E S E N T A T I O N
November 3, 2026
B S E S C R I P C O D E : 5 0 0 6 7 2
I M P O R T A N T N O T I C E
Disclaimer
This presentation has been prepared by the management of Evonile Pharma Limited (formerly know as Novartis India Limited) (the “Company” or
“Evonile”) solely for the information of the recipients. No representation or warranty, express or implied, is made as to, and no reliance should be placed on,
the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all
events not current after the date of this presentation.
Certain statements made in this presentation may not be based on historical information or facts and may be “forward-looking statements” based on the
currently held beliefs and assumptions of the management of the Company, which are expressed in good faith and in their opinion reasonable, including
those relating to the Company’s general business plans and strategy, its future financial condition and growth prospects, and future developments in its
industry and its competitive and regulatory environment.
Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition,
performance or achievements of the Company or industry results to di(cid:257)er materially from those expressed or implied by such statements, including future
changes or developments in the Company’s business, its competitive environment and political, economic, legal and social conditions. Past performance is
not necessarily indicative of future results. The Company disclaims any obligation to update these forward-looking statements to reflect future events or
developments.
This presentation is for general information purposes only, without regard to any specific objectives, financial situations or informational needs of any
particular person, and does not constitute an o(cid:257)er or invitation to purchase or subscribe for any securities. No part of it should form the basis of, or be relied
upon in connection with, any investment decision or any contract or commitment to purchase or subscribe for any securities.
Evonile Pharma Limited · Investor Presentation 2
Where potential peaks
Evonile Pharma Limited · Investor Presentation
C O M P A N Y O V E R V I E W
Company snapshot
Scaled, Market-leading
House with a Long Legacy
Brands
Years since India-focused
79+ 100%
founding business
Years listed on the Brands with ₹30 cr+
43 6
BSE Revenue1
Evonile Pharma Limited · Investor Presentation (1) As per IQVIA MAT Sep’26 4
C O M P A N Y O V E R V I E W
Legendary Brands, Untapped Focus
DECADES OF HERITAGE PRESCRIBER EQUITY INTACT UNTAPPED POTENTIAL
• Decades-old portfolio; several brands • High unaided recall among HCPs • Previously taken to market via partner-
set the reference standard in their led, outsourced distribution
• Prescription pull sustained with minimal
category
recent promotion • Brands have untapped headroom
• Original-molecule pedigree anchors
• Awareness spans metro, Tier 1 and Tier
brand identity and quality perception
2, beyond key accounts
• Deep-rooted familiarity across
prescribers and chemists nationwide
THE ACTIVATION GAP:
• No dedicated field force behind these brands today; demand runs on legacy prescriber loyalty alone
• Re-establishing in-house, focused promotion is the platform's single largest value unlock
Evonile Pharma Limited · Investor Presentation 5
B R A N D P O R T F O L I O
Flagship brands hold leadership across priority therapies
Cardiology Pain Management Gynaecology Wellness (VMN) Neuro (CNS) Transplant
RPM: 11,398 Cr+ RPM: 1,696 Cr+ RPM: 155 Cr+ RPM: 2,840 Cr+ RPM: 585 Cr+ RPM: 975 Cr+
Calcium-
Minipress XL® Voveran® Methergin® Tegrital® Myfortic
Sandoz®
Orals Orals, Injectables, Topicals Orals, Injectables Injectables Orals Orals
#1 #1
#1 #1 #1 #1
CVM rank CVM rank
CVM rank CVM rank CVM rank CVM rank
Macalvit® Simulect
Orals Injectables
#1 #1
CVM rank CVM rank
Evonile Pharma Limited · Investor Presentation (1) Source: IQVIA TSA MAT Sep’26; RPM: Internal Represented Market; CVM: Covered Market 6
C O M P A N Y O V E R V I E W
Financial snapshot
Revenue From Operation and PAT (₹ crore)
Revenue CAGR FY23-26
356 354
PAT CAGR FY23-26
103 101
Net cash as of Mar’26
FY23 FY24 FY25 FY26
Revenue From Operation PAT
Evonile Pharma Limited · Investor Presentation 7
B U S I N E S S P E R F O R M A N C E
A transition quarter: brands back in-house, Minipress XL added, field force being built
Q 2 A N D H 1 F Y 2 7
MD & CEO’s message
Following the transition from Novartis AG, Evonile Pharma has made substantial progress in just a few months. We are transitioning
from a single-customer-dependent business model to an independent pharmaceutical company with our own distribution, sales and
marketing capabilities. This shift requires a new organizational foundation, and the key building blocks are being put in place. These
capabilities will provide the foundation for establishing Evonile as one of India’s progressive and forward-looking domestic
pharmaceutical companies.
During the quarter, we completed two strategic transactions: the acquisition of Minipress XL and an ophthalmology in-licensing
agreement. Both strengthen our portfolio and create new platforms for sustainable growth.
In H2 FY27, our focus will be on completing the organizational build-out, establishing an appropriate cost structure and bringing
together a strong leadership & operating team to drive Evonile’s next phase of growth. We are laying the foundations of an
organization with the capabilities, ambition and strategic direction to unlock the full potential of Evonile Pharma.”
Dr. Vikas Gupta
Dr. Vikas Gupta
Managing Director & CEO
Evon
[Showing first 8,000 characters — download PDF for full document]